Small molecules targeting glycogen synthase kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa

Miguel Marchena, Beatriz Villarejo‐Zori, Josefa Zaldívar-Díez, Carmen Gil, Catalina Hernández‐Sánchez, Ana Martı́nez, Enrique J. de la Rosa

Journal of Enzyme Inhibition and Medicinal Chemistry · 2017 · 25 citations · 25 references

DOIFull text

Open access

Concepts

Abstract

Retinitis pigmentosa (RP) is an inherited retinal dystrophy that courses with progressive degeneration of retinal tissue and loss of vision. Currently, RP is an unpreventable, incurable condition. We propose glycogen synthase kinase 3 (GSK-3) inhibitors as potential leads for retinal cell neuroprotection, since the retina is also a part of the central nervous system and GSK-3 inhibitors are potent neuroprotectant agents. Using a chemical genetic approach, diverse small molecules with different potency and binding mode to GSK-3 have been used to validate and confirm GSK-3 as a pharmacological target for RP. Moreover, this medicinal chemistry approach has provided new leads for the future disease-modifying treatment of RP.

References

25